Citius Oncology reports Q2 FY2026 net loss $26.6M; LYMPHIR revenue $1.7M, launch progressing

CITIUS ONCOLOGY, INC.

2026-Q2 EPS reported -$0.34 revenue$5,611,409

Net product revenues $1.7M in Q2 ($5.6M H1) vs $0 prior year; gross margin 80%.
Net loss $26.6M vs $7.7M prior year, driven by $19.7M one-time CMO contract cancellation.
Cash $2.6M at March 31; subsequent $11.5M warrant exercise and $10M debt tranche from Avenue Capital ($25M facility).
83% of target accounts on formulary or in review; near 100% payer coverage; initial European shipment.
Hired Jefferies as exclusive financial advisor to evaluate strategic alternatives; combined cash runway through Nov 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.